You are here

P&T October 2012

Features

Editorial
Legal and Health Care Challenges

The growing abuse of toxic stimulants known as “bath salts” can cause psychosis and possibly death. Raising awareness of the dangers through patient counseling and community outreach programs will be important—especially efforts aimed at young people.

New Federal Reductions Might Compound the Stress
Hospitals, low-income families, and disabled individuals who rely on Medicaid funding will be struggling financially if the government reduces its outlays to the states by $800 billion over the next 10 years in order to reduce the federal deficit.
First Report of a Case of Rhabdomyolysis

A 70-year-old man with a history of fibromyalgia, type-2 diabetes mellitus, hypercholesterolemia, and chronic low back pain presented to the emergency department with altered mental status, limb weakness, twitching, and slurred speech. The authors sought to determine whether his rhabdomyolysis resulted from an adverse reaction associated with pregabalin and simvastatin.

Part 2: Current and Future Clinical Applications

Although many nanotherapeutic and nanodiagnostic agents are in use and have the potential to improve health care, many barriers have impeded the development and availability of these products. Despite these impediments, it is expected that nanomaterials will become an integral part of mainstream medicine.

Meeting Highlights
Topics include antiplatelet drugs for acute coronary syndrome, renal denervation for hypertension, contrast-induced nephropathy, “e-cigarettes,” and resistant hypertension.

Departments

Medication Errors
Many mistakes can result from “inattentional blindness.”
Prescription: Washington
Hospitals are paying exorbitant prices for drugs because of an insidious “gray market” pipeline.

FDA approvals, drug indications, and updates

Truvada for HIV prevention, Xtandi for metastatic castration-resistant prostate cancer, and Marqibo, a vincristine liposome injection for acute myelogenous leukemia

Drug Forecast
Ticagrelor (Brilinta) for acute coronary syndrome